AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
London close: FTSE finishes flat ahead of Trump tariff deadline
4 July 2025 17:48
(Sharecast News) - London stocks ended Thursday little changed at the top tier but weaker further down the board, as investors weighed fresh economic data and cautious sentiment ahead of Donald Trump's...
-
AstraZeneca's Imfinzi gets EU green light
4 July 2025 07:10
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.
-
AstraZeneca's Datroway gets green light from FDA
24 June 2025 07:10
(Sharecast News) - Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer.
-
AstraZeneca launches strategic research collaboration with China's CSPC Pharmaceuticals
13 June 2025 09:51
(Sharecast News) - Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group.
-
AstraZeneca's Calquence receives European Commission approval
6 June 2025 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a...
-
EU recommends AstraZeneca bladder cancer treatment for approval
27 May 2025 08:36
(Sharecast News) - EU regulators have recommended AstraZeneca's Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).
-
London close: Stocks finish choppy week in the black
16 May 2025 16:32
(Sharecast News) - London equities ended the week higher on Friday, supported by gains in pharmaceutical and energy stocks.
-
London close: Stocks rally on US-China tariff deal
12 May 2025 16:30
(Sharecast News) - London stocks ended higher on Monday as investors welcomed news of a temporary trade agreement between the United States and China that will see a rollback of some tariffs.
-
Pharma stocks slide as Trump threatens price cuts in US
12 May 2025 10:13
(Sharecast News) - Shares in pharmaceutical companies fell on Monday after US President Donald Trump threatened to sign an executive order to slash the price of prescription drugs for Americans.
-
Sunday newspaper round-up: US-China, Aerospace, Pharma
11 May 2025 14:38
(Sharecast News) - The US president said talks with China that were taking place in Geneva had achieved a "total reset" in the two countries' trade relations. Without elaborating, Donald Trump...
-
London close: FTSE snaps 16-day win streak ahead of Fed
7 May 2025 15:05
(Sharecast News) - London stocks ended lower on Wednesday, with the top-flight index snapping a 16-day winning streak as investor caution ahead of the US Federal Reserve's policy decision weighed on...
-
GSK, AstraZeneca slide after FDA unveils new vaccine lead
7 May 2025 11:32
(Sharecast News) - Shares in GSK and AstraZeneca came under pressure on Wednesday, after vaccine-sceptic Vinay Prasad was appointed to a key role at the US Food and Drug Administration.
Company announcements Announcements
-
Imfinzi approved in the EU for bladder cancer
4 July 2025 07:00
AstraZeneca
-
Total Voting Rights
1 July 2025 15:00
AstraZeneca
-
Datroway approved in US for EGFRm lung cancer
24 June 2025 07:00
AstraZeneca
-
Holding(s) in Company
17 June 2025 11:45
AstraZeneca
-
AstraZeneca enters into collaboration with CSPC
13 June 2025 09:30
AstraZeneca
-
Director/PDMR Shareholding
12 June 2025 15:00
AstraZeneca
-
Fixed-duration Calquence approved in EU for 1L CLL
6 June 2025 07:00
AstraZeneca
-
Block listing Interim Review
2 June 2025 15:05
AstraZeneca
-
Total Voting Rights
2 June 2025 15:00
AstraZeneca
-
Imfinzi recommended in EU for bladder cancer
27 May 2025 07:00
AstraZeneca
-
Director/PDMR Shareholding
23 May 2025 10:00
AstraZeneca
-
Director Declaration
21 May 2025 13:45
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.